View Post

New Asthma Indication for Triple-Ingredient Inhaler May Increase Orosystemic Complications

Recently, the Food and Drug Administration (FDA) approved the supplemental New Drug Application for Trelegy Ellipta® for the maintenance treatment of asthma in patients aged 18 years and older. This new indication is in addition to Trelegy Ellipta®’s previous indication for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. This new indication, and resulting increased market demand, …